samedan logo
 
 
spacer
home > pmps > spring 2021 > top trends in pharma production in 2021
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Top Trends in Pharma Production in 2021

“There is nothing more constant than change,” Charles Darwin once said. In the pharmaceutical industry, times have rarely been as turbulent as they currently are. In addition to the comprehensive initiatives to contain and control the coronavirus, three key trends are shaping the industry.

Increased Demand for Personalised Medicine

Firstly, Big Pharma will produce fewer large batches of tablets or bestsellers in the future. Instead, there will be increased demand for personalised tablets. The IQVIA Institute for Human Data Sciences predicts that by 2025, more than 60% of spending on new drug launches will be allocated to the ‘specialty drugs’ group (1). These are mainly oncological therapeutics, or drugs for rare diseases or for the therapy of autoimmune diseases. Therefore, there will be less demand for large-scale or mono-product facilities. Rather, what are needed are smaller, highly complex plants that can produce as quickly and safely as possible and be cleaned automatically.

Secondly, the demand for machines that can process active or highly potent ingredients continues to rise. More than 60% of pharma products are produced as tablets, capsules, coated tablets, or similar. Particularly in the case of newer products, active pharmaceutical ingredients (APIs) are becoming increasingly effective. In some areas, the market segment for high potency APIs is growing at double-digit rates, mainly driven by oncology drugs (2).

The third much-discussed trend topic is continuous manufacturing (CM). After being discussed only as a future strategy for a long time, continuous processes are increasingly used in pharmaceutical solids production.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tobias Borgers is Head of Marketing at L.B. Bohle with a huge experience of multi-channel marketing initiatives. Proven abilities in creating successful exhibitions, integrated digital and traditional marketing campaigns, social media marketing, content management, lead generation, event, and project management, Tobias holds a BA from University of Duisburg-Essen, Germany, and joined L.B. Bohle in 2012.
spacer
Tobias Borgers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Grupo NotreDame Intermédica (GNDI) of Brazil enhances patient care and improves patient access to leading-edge medications by joining Clinerion’s global network of hospital partners on Patient Network Explorer

Grupo NotreDame Intermédica (GNDI) is the largest healthcare operator in Brazil, with 6.4 million members. Founded in 1968, it is a pioneer in preventive medicine. GNDI has a wide offer, comprising 29 hospitals, 88 clinical centers, 23 autonomous emergency rooms, 15 preventive medicine centers and 2 health centers exclusively dedicated to the over-fifties.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement